Status:
UNKNOWN
The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients
Lead Sponsor:
Fudan University
Conditions:
Colorectal Cancer
Liver Metastases
Eligibility:
All Genders
18-79 years
Brief Summary
establishment and validation of the prediction model of avastin plus chemotherapy as first line treatment in simultaneous ras mutant unresectable CRLM patients
Detailed Description
Ras mutant unresectable CRLM patients with primary tumor resection followed by avastin in combination with chemotherapy were included in this study. The tumor response was assessed by local MDT group....
Eligibility Criteria
Inclusion
- age 18-75 years, histologically proven colorectal adenocarcinoma, with liver-dominant disease, a life expectancy of \> 3 months, ras mutation, unresectable simultaneous liver metastasis, ECOG 0-1, written informed consent for participation in the trial.
Exclusion
- patients with known hypersensitivity reactions to any of the components of the study treatments, pregnancy or breast-feeding, accepted chemotherapy, radiotherapy and target therapy before primary tumor resection, other previous malignancy within 5 years, known drug abuse/alcohol abuse, ECOG\>1, legal incapacity or limited legal capacity.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04525313
Start Date
August 1 2020
End Date
December 1 2022
Last Update
August 25 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.